Skip to content

Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study

Optimal Wound Care After Simplex or Modified Radical Mastectomy With or Without Axillary Lymphadenectomy Placement of a Drain Versus the Use of Adaptive Skin Sutures; a Prospective Randomised Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01509781
Enrollment
400
Registered
2012-01-13
Start date
2011-09-30
Completion date
Unknown
Last updated
2015-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

in Situ Breast Cancer, Invasive Breast Cancer

Keywords

simple mastectomy, modified radical mastectomy, wound care, suction drain, adaptive suture

Brief summary

The objective of this prospective randomized study is to perform qualitative and quantitative comparisons between the insertion of traditional suction drains (Arm: Suction drain) versus the application of absorbable adaptive sutures (Arm: Adaptive suture) following simplex mastectomy or modified radical mastectomy in the light of the total volume of withdrawn serum from wound cavity, the extent of early postoperative analgesic requirements and quality of life.

Interventions

PROCEDUREInsertion of suction drain(s) following mastectomy

One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.

PROCEDUREAdaptive skin sutures.

Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.

Sponsors

National Institute of Oncology, Hungary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 75 Years
Healthy volunteers
No

Inclusion criteria

* female patients with primary unilateral, stage 0, I or II, T3N1M0 breast cancer necessitating simple or modified radical mastectomy

Exclusion criteria

* age above 75 years and bad general state * pregnancy * autoimmune disease * non-radical excision * mastitis carcinomatosis * lymphangitis carcinomatosis * wound infection necessitating treatment

Design outcomes

Primary

MeasureTime frameDescription
Total amount of sera withdrawn from the wound cavity4 weeksBy each follow-up visit within the indicated time frame, the punctuated serum is collected and its volume is measured by a measuring cylinder acquired from the Pharmacy Department and data is recorded. At the end of the follow-up period, the total amount of serum (mL) is documented.

Secondary

MeasureTime frameDescription
Number of punctions following the removal of suction drain, and total volume of punctuated seroma (mL)4 weeks
Rate of local wound complications.4 weeks
Extent of early postoperative analgesic requirements4 daysAssessment of analgesic consumption to achieve adequate pain relief for each patient. Pain relief is carried out according to institutional protocol and includes: diclofenac sodium, diclofenac sodium + orphenadrine, nalbuphine, metamizole sodium, paracetamole, tramadole.
Mobility of the shoulder on the side of the operated side4 weeksAssessing shoulder motion on the 1st postoperative day, then weekly for 4 weeks. Abduction 1: 0°- 45° Abduction 2: 45° - 90° Abduction 3: 90° - 135° Abduction 4: 135° - 180°
Cost analysis4 weeksSuction drain, suction flask, syringes, number of patient-doctor consultations
Assessment of quality of life in the early postoperative period4 weeksUsing EORTC QoL BR23, weekly for 4 weeks following surgery.

Countries

Hungary

Contacts

Primary ContactZoltan Matrai, M.D.
matraidoc@gmail.hu+36 1 224 8600
Backup ContactLaszlo Toth, M.D., Ph.D.
toth.l@oncol.hu

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026